CureVac Management
Management criteria checks 2/4
CureVac's CEO is Alexander Zehnder, appointed in Apr 2023, has a tenure of 1.67 years. total yearly compensation is €978.33K, comprised of 51.1% salary and 48.9% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth $161.78K. The average tenure of the management team and the board of directors is 1.8 years and 8.8 years respectively.
Key information
Alexander Zehnder
Chief executive officer
€978.3k
Total compensation
| CEO salary percentage | 51.1% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.8yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
CureVac: Back To Square One
Oct 08CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€278m |
| Mar 31 2024 | n/a | n/a | -€273m |
| Dec 31 2023 | €978k | €500k | -€260m |
Compensation vs Market: Alexander's total compensation ($USD1.02M) is below average for companies of similar size in the US market ($USD3.24M).
Compensation vs Earnings: Insufficient data to compare Alexander's compensation with company performance.
CEO
Alexander Zehnder (54 yo)
1.7yrs
Tenure
€978,331
Compensation
Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Member of Management Board | 1.7yrs | €978.33k | 0.025% $ 161.8k | |
| COO, Member of Management Board & MD | 3.4yrs | €600.74k | 0.0038% $ 24.5k | |
| Chief Scientific Officer | 1.9yrs | €614.49k | 0.0021% $ 13.6k | |
| Senior VP & Area Head of Oncology | 1.9yrs | €284.15k | no data | |
| CFO & Member of Executive Board | less than a year | no data | no data | |
| Chief Business Officer & Member of Executive Board | less than a year | no data | no data | |
| Vice President Corporate Communications & Investor Relations | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Head of Corporate Communications | no data | no data | no data | |
| Head of Human Resources | no data | no data | no data | |
| Senior Vice President of Technology | no data | no data | no data | |
| Senior Vice President of Science & Innovation | no data | no data | no data |
1.8yrs
Average Tenure
57yo
Average Age
Experienced Management: CVAC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Scientific Director of Immunology and Member of Scientific Advisory Board | no data | no data | no data | |
| Supervisory Board Member | 5.5yrs | €96.25k | 0.0043% $ 27.7k | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Independent Director of Supervisory Board | 1.5yrs | €51.03k | 0.0019% $ 12.0k | |
| Independent Chairman of Supervisory Board | 9.3yrs | €123.75k | 0.0075% $ 48.1k | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Supervisory Board Member | 9.3yrs | €96.25k | 0.0048% $ 31.1k | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data |
8.8yrs
Average Tenure
64yo
Average Age
Experienced Board: CVAC's board of directors are considered experienced (8.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CureVac N.V. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlie Yang | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |
| Martin Auster | Credit Suisse |